Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Stock Report

Mkt Cap: US$949.7m

Collegium Pharmaceutical Financial Health

How is Collegium Pharmaceutical's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: COLL's short term assets ($405.2M) do not cover its short term liabilities ($414.5M).

Long Term Liabilities: COLL's short term assets ($405.2M) do not cover its long term liabilities ($589.2M).


Debt to Equity History and Analysis

Debt Level: COLL's net debt to equity ratio (298.9%) is considered high.

Reducing Debt: COLL's debt to equity ratio has increased from 2.2% to 366.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable COLL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: COLL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 12.1% per year.


Discover healthy companies